1. ？Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement:Idiopathic Pulmonary Fibrosis:Evidence based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med,2011,183:788-824.
[2]
2. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med,2006,174:810-816.
[3]
3. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE):a multicentre, randomised, placebo-controlled trial. Lancet,2009,374:222-228.
[4]
4. King TE Jr, Brown KK, Raghu G, et al. BUILD-3:a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med,2011,184:92-99.
[5]
5. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept:an exploratory, placebo-controlled trial. Am J Respir Crit Care Med,2008,178:948-955.
[6]
6. Zisman DA, Schwarz M, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med,2010,363:620-628.
[7]
7. Luppi F,pagnolo P,Cerri S, et al. The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med, 2012,18:428-432.
[8]
8. Raqhu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone:results of a prospective, open-label Phase Ⅱ study. Am J Respir Crit Care Med,1999,159:1061-1069.
[9]
9. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med,2002,41:1118-1123.
[10]
10. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med,2005,171:1040-1047.
[11]
11. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary Fibrosis (CAPACITY):two randomised trials. Lancet,2011,577:1760-1769.
[12]
12. Higgins J, Green S. Cochrane Collaboration:Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011].John Wiley\&Sons Ltd and The Cochrane Collaboration, Chichester, 2011.
[13]
13. Liedman R, Hansson SR, Howe D, et al. Endometrial expression of vasopressin, oxytocin and their receptors in patients with primary dysmenorrheal and healthy volunteers at ovulation. Eur J Obstet Gynecol Reprod Biol,2008,137:189-192.
[14]
14. Higgim JP, Airman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ,201l,343:d5928.
16. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J,2010,35:821-829.
[17]
17. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab,2002,76:234-242.
[18]
18. O'Brien K, Troendle J, Gochuico BR, et al. Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab,2011,103:128-134.
[19]
19. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med,2014,370:2083-2092.
[20]
20. Jiang C, Huang H, Liu J, et al. Adverse events of pirfenidone for the treatment of pulmonary fibrosis:a meta-analysis of randomized controlled trials. PLoS One,2012,7:e47024.
